HighTower Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

HighTower Advisors’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,960	Closed	-$92K	–	3879
2026 Q1	$92K	Sell	14,960 -40	-0.3%	-$309	﹤0.01%	3649
2025 Q4	$116K	Hold	15,000	–	–	﹤0.01%	3481
2025 Q3	$140K	Hold	15,000	–	–	﹤0.01%	3468
2025 Q2	$125K	Buy	+15,000	New	+$103K	﹤0.01%	3425

Other funds holding FENC

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HFM

Hartford Financial Management Hartford, Connecticut $448M AUM 32.11% 1-Year Est. Return

Eleva Capital Paris, France $343M AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

HighTower Advisors's FENC Position: Q2 2026 in Review

HighTower Advisors sold out of Fennec Pharmaceuticals (FENC) in Q2 2026, closing a stake of 14,960 shares — an estimated $92K sold.

HighTower Advisors first reported a position in FENC in Q2 2025 and held it in 4 quarters. The position peaked at $140K in Q3 2025. 33 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

HighTower Advisors reported no remaining Fennec Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HighTower Advisors sold 14,960 Fennec Pharmaceuticals shares in Q2 2026, an estimated $92K.
HighTower Advisors first reported a position in Fennec Pharmaceuticals in Q2 2025 and held it in 4 quarters.
HighTower Advisors's Fennec Pharmaceuticals position peaked at $140K in Q3 2025.
33 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.